Biosimilar Industry Critiques Biden's Drug Pricing Reforms
Specialty tiers for biosimilars and reforms that address the proliferation of poor-quality patents would help lower costs and improve access, biosimilar industry veterans said.
Fed Expert Describes Improving Regulatory, Policy Structure for Biosimilars
Prior to the turmoil of the pandemic, the FDA and CMS were at work on shoring up the biosimilars market, and this work continues on various fronts, a regulatory/policy expert explains.
Burich: Saving Grace for Biosimilars in 2021 Will Be Bipartisan Support
Despite a rocky power transition at the federal level, the compass heading for biosimilars is unchanged, said policy expert Molly Burich.
Azar Says Trump's Drug Price Shake-up Is Working
HHS Secretary Alex M. Azar said efforts and policies to counter a sharply upward drug price trend have been successful, in a talk with the Association for Accessible Medicine.
OTBB Director Discusses FDA's Roadmap for Biosimilars
Sarah Yim, MD, director of the Office of Therapeutic Biologics and Biosimilars (OTBB), highlighted the ways the FDA is working to remove blocks and wedges hindering biosimilars.
2 Commerce Drive Cranbury, NJ 08512